Baidu
map

一滴血验出 13 种癌症:日本开发诊断癌症新方法

2017-08-24 中国新闻网 中国新闻网

据日媒报道,近日,日本国立癌症研究中心等的团队研发出通过一滴血就能同时诊断 13 种癌症的检测方法。报道称,该方法是对癌症分泌的微小物质进行检查。据悉与使用“肿瘤标志物”的现行血液检查相比,其优点是发现率更高,能发现极为早期的癌症。

据日媒报道,近日,日本国立癌症研究中心等的团队研发出通过一滴血就能同时诊断 13 种癌症的检测方法。报道称,该方法是对癌症分泌的微小物质进行检查。据悉与使用“肿瘤标志物”的现行血液检查相比,其优点是发现率更高,能发现极为早期的癌症。

该团队计划以癌症患者等为对象推进临床研究,希望在数年内获得国家认证。上述中心该研究负责人落谷孝广表示:“这将成为患者身体负担小且较为廉价的检查。若能早期发现,就可进行更为有效的治疗,有利于削减医疗费用。”

据了解,肿瘤标志物检查主要检测癌细胞死亡时出现的蛋白质,因此癌症不发展到一定程度就难以发现,还存在准确性的问题。

该团队着眼于癌细胞在血液中分泌的被称为“微小 RNA(核糖核酸)”的物质。利用冷冻保存在国立癌症研究中心及国立长寿医疗研究中心等的约 4.3 万人的血液,调查了乳腺癌、大肠癌等 13 种癌特有的微小 RNA。

经研究发现每种癌都有 2~10 种特有的微小 RNA。通过调查分泌量的变化,均以 95% 左右的准确度发现了各种癌症。这 13 种癌症包括胃癌、食道癌、肺癌、肝癌、胆道癌、胰腺癌、大肠癌、卵巢癌、前列腺癌、膀胱癌、乳腺癌、肉瘤、神经胶质瘤。

如果使用人工智能 (AI) 分析分泌量,则有可能进一步提高检查精确度。

报道指出,然而长期保存的血液中微小 RNA 有可能发生变质。因此将推进临床研究,采集新被诊断为癌症等的 3000 多人的新鲜血液,调查是否有效。现阶段无计划以一般人为对象开展研究。据悉团队力争首先作为乳腺癌的检测方法获得认证。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1813051, encodeId=924a1813051cd, content=<a href='/topic/show?id=d206916403e' target=_blank style='color:#2F92EE;'>#诊断癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91640, encryptionId=d206916403e, topicName=诊断癌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Dec 13 10:26:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903261, encodeId=179c1903261d8, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Aug 30 08:26:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237712, encodeId=8f7323e712f0, content=学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3172133705, createdName=1531fd4af8m, createdTime=Sun Aug 27 13:14:45 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294354, encodeId=b2f61294354d3, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Aug 26 10:26:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236964, encodeId=8063236964ca, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Fri Aug 25 12:12:11 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1813051, encodeId=924a1813051cd, content=<a href='/topic/show?id=d206916403e' target=_blank style='color:#2F92EE;'>#诊断癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91640, encryptionId=d206916403e, topicName=诊断癌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Dec 13 10:26:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903261, encodeId=179c1903261d8, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Aug 30 08:26:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237712, encodeId=8f7323e712f0, content=学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3172133705, createdName=1531fd4af8m, createdTime=Sun Aug 27 13:14:45 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294354, encodeId=b2f61294354d3, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Aug 26 10:26:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236964, encodeId=8063236964ca, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Fri Aug 25 12:12:11 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1813051, encodeId=924a1813051cd, content=<a href='/topic/show?id=d206916403e' target=_blank style='color:#2F92EE;'>#诊断癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91640, encryptionId=d206916403e, topicName=诊断癌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Dec 13 10:26:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903261, encodeId=179c1903261d8, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Aug 30 08:26:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237712, encodeId=8f7323e712f0, content=学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3172133705, createdName=1531fd4af8m, createdTime=Sun Aug 27 13:14:45 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294354, encodeId=b2f61294354d3, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Aug 26 10:26:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236964, encodeId=8063236964ca, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Fri Aug 25 12:12:11 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2017-08-27 1531fd4af8m

    学习了.

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1813051, encodeId=924a1813051cd, content=<a href='/topic/show?id=d206916403e' target=_blank style='color:#2F92EE;'>#诊断癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91640, encryptionId=d206916403e, topicName=诊断癌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Dec 13 10:26:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903261, encodeId=179c1903261d8, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Aug 30 08:26:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237712, encodeId=8f7323e712f0, content=学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3172133705, createdName=1531fd4af8m, createdTime=Sun Aug 27 13:14:45 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294354, encodeId=b2f61294354d3, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Aug 26 10:26:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236964, encodeId=8063236964ca, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Fri Aug 25 12:12:11 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1813051, encodeId=924a1813051cd, content=<a href='/topic/show?id=d206916403e' target=_blank style='color:#2F92EE;'>#诊断癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91640, encryptionId=d206916403e, topicName=诊断癌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Dec 13 10:26:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903261, encodeId=179c1903261d8, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Aug 30 08:26:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237712, encodeId=8f7323e712f0, content=学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3172133705, createdName=1531fd4af8m, createdTime=Sun Aug 27 13:14:45 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294354, encodeId=b2f61294354d3, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Aug 26 10:26:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236964, encodeId=8063236964ca, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuCkPCv9CVFBmWOibyBArQwSeQLxvxz9OaumlaSUZjfCWTxbXduhuG2xCJUPs1nB9nd4gxZknH7IZj/0, createdBy=52281985209, createdName=damiao93, createdTime=Fri Aug 25 12:12:11 CST 2017, time=2017-08-25, status=1, ipAttribution=)]
    2017-08-25 damiao93

    学习了.谢谢分享

    0

相关资讯

4大疾病领域基因疗法管线大盘点

自转基因技术于上世纪70年代问世以来,基因疗法就被视为解决许多疾病,尤其是遗传病的终极疗法。过去二三十年来基因工程领域取得了突飞猛进的发展,但是,将基因疗法应用到人身上的过程却并非一帆风顺。基因疗法的长期有效性和长期安全性是这一领域的主要瓶颈。 2017年对于基因疗法来说可能是里程碑的一年,美国FDA有望批准Spark公司voretigene neparvovec用于治疗由RPE65突变引起

Nature:新型DNA标签证实血液中细胞发育树的存在

血液中多种不同的细胞类型是如何发育的?科学家们长期以来一直在研究这个问题。根据经典的模型,不同的发育路线像树一样分枝。树干由干细胞组成,树枝由各种不同的祖细胞组成,这些祖细胞可以产生许多不同的细胞类型。然后,它又进一步分化成特殊的血细胞,即红细胞、血小板和免疫系统的各种白细胞。然而,近年来,人们对这种模式产生了怀疑。

STM封面:测序方法TEC SEQ让癌症的血液检测又往前一步

为了实现无创的方法早期检测癌症,Johns Hopkins Kimmel癌症中心的科学家报道他们已经开发了一个能测试血液中微量肿瘤特异性DNA的检测,已经用它来准确识别138人中超过一半患有相对早期的结直肠癌、乳腺癌、肺癌和卵巢癌。科学家说,这项试验的创新之处是它能区分肿瘤脱落的DNA和其它被误认为是癌症生物标记的DNA。

Am J Clin Nutr:优化维生素D状态 **维生素D2还是维生素D3?

维生素D2和维生素D3是否在增加和维持血清25-羟基维生素D [25(OH)D]浓度中有同等效果,尤其是较低剂量的维生素D,相关文献得出的结论是矛盾的。2017年8月,发表在《Am J Clin Nutr.》的一项为期12周的随机、安慰剂对照食品强化试验调查了健康南亚人和欧洲白种女性中,每天补充15μg维生素D2 vs维生素D3增加冬季25-羟维生素D状态。

Cancer Cell:了解肺癌,这个血液指标很关键!

荷兰的研究人员设计了不同的液体活检方法。通过检测血液循环血小板(也称为血栓细胞)吸收的肿瘤RNA,他们的测试(称为thromboSeq)不是在血液中寻找癌症DNA或其他生物标志物的证据,而是可以以接近90%的准确度诊断非小细胞肺癌。非小细胞肺癌占肺癌的绝大多数。该研究在8月14日刊登在癌症细胞杂志上。

2017 BCSH指南:血小板输注

2017年2月,英国血液学标准委员会(BCSH)发布了血小板输注指南,旨在为临床血小板输注提供实践指导,减少不恰当的使用。指南主要内容涉及预防性血小板输注,治疗性血小板输注,血小板输注风险等。

Baidu
map
Baidu
map
Baidu
map